Rivkin Investment Podcast

Rifkin on AI sell-off, ASX small caps, and AMPOL cyclical risks

13 min Listen to the original Episode page
AI stocksPrivate equityAustralian small capsMaine PharmaAMPOLBond yieldsCyclical stocks

Summary

Shannon Rifkin discusses the recent sell-off in US AI stocks, accelerated by Jensen Huang's resignation from NVIDIA. She notes a divergence in bond yields, with US yields strengthening due to sticky inflation, while Australia is priced for rate cuts. Rifkin highlights a surge in private equity bids for undervalued Australian small and mid-cap stocks. She recommends buying Maine Pharma at ~$6, citing a new binding deal with Gede Richter. Rifkin also describes AMPOL as a cyclical stock, attributing current high refiner margins to supply disruptions from the 'Iran war'.

Episode sections

  1. 0:00 – 2:24

    Market Overview: AI Sell-off and Rate Divergence

    Shannon Rifkin discusses the recent sell-off in US AI stocks, accelerated by Jensen Huang's resignation from NVIDIA, which dragged down the S&P 500 and NASDAQ. She notes a divergence in bond yields, with US yields strengthening due to sticky inflation, while Australia is priced for rate cuts next year despite current economic weakness.

  2. 2:24 – 3:43

    Private Equity Activity and ASX Small Caps

    The speaker observes a surge in private equity bids for undervalued Australian small and mid-cap stocks, filling the void left by a lack of IPOs. She warns that the ASX may become less relevant if capital flows only to large caps, leaving smaller companies to 'drop like flies' without market support.

  3. 3:43 – 7:38

    Maine Pharma Deal Analysis and Recommendation

    Rifkin recommends buying Maine Pharma at ~$6, citing a new binding deal with Gede Richter. She contrasts this with the previous failed COSSET deal, arguing the new buyer is a better fit and the deal is 'rock solid,' offering a high annualized return despite past trauma.

  4. 7:38 – 10:25

    Investment Strategy: Emotion vs. Fundamentals

    Addressing a question on using trailing sell orders for Maine Pharma, Rifkin advises against emotional trading. She argues the new deal has stronger protections than the previous one and suggests investors should analyze the reason for any price drops rather than automatically selling.

  5. 10:25 – 13:18

    AMPOL: Cyclical Nature and Iran War Impact

    Rifkin describes AMPOL as a cyclical stock, not a defensive one, noting its dividend depends on earnings. She attributes current high refiner margins to supply disruptions from the 'Iran war' and predicts a significant sell-off in AMPOL when oil prices drop as the conflict ends.

Assets discussed

AssetKindStanceContext
S&P 500indexbearishso it has certainly driven uh dragged down the SP five hundred and the NASDAQ, obviously, more specifically.

“Stance” is how the speakers talked about the asset, not a recommendation.

Claims worth verifying

Jensen Huang resigned from NVIDIA, accelerating the AI sector sell-off.

Unidentified speaker (UNKNOWN) ·0:28

How to verify: Check NVIDIA press releases or news archives for Jensen Huang's resignation announcement date and subsequent stock performance data. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

US bond yields have strengthened recently due to sticky inflation, while Australia is priced for rate cuts next year.

Unidentified speaker (UNKNOWN) ·1:15

How to verify: Compare US Treasury yield curves and Australian Reserve Bank cash rate expectations/forecasts for late 2026/early 2026. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Maine Pharma is recommended for purchase at approximately $6.

Shannon Rifkin ·3:43

How to verify: Check ASX trading data for Maine Pharma's share price around the podcast date (Nov 19, 2026) and any relevant analyst reports. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Maine Pharma previously had a failed takeover deal with COSSET.

Shannon Rifkin ·4:01

How to verify: Search ASX announcements for Maine Pharma's historical takeover attempts and litigation outcomes involving COSSET. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

COSSET made a bluff about closing a factory in South Australia, which scared the South Australian Premier.

Shannon Rifkin ·5:20

How to verify: Review news reports from the time of the COSSET deal regarding statements by the South Australian Premier and Treasurer, and verify if the factory was actually closed. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Maine Pharma had already announced the sale of a division including the factory before the new Gede Richter deal.

Shannon Rifkin ·5:45

How to verify: Check ASX announcements for Maine Pharma regarding the sale of assets/divisions prior to the Gede Richter deal announcement. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Gede Richter licenses and sells Maine Pharma's Nextelos product.

Shannon Rifkin ·6:33

How to verify: Review Gede Richter's investor presentations or press releases confirming licensing agreements for Nextelos. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

AMPOL pays a 60-65% dividend payout ratio.

Unidentified speaker (UNKNOWN) ·10:57

How to verify: Calculate AMPOL's dividend payout ratio using its latest annual financial report (dividends per share divided by earnings per share). For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

The 'Iran war' is causing supply disruptions in oil markets, driving up refiner margins.

Shannon Rifkin ·11:17

How to verify: Analyze global oil price indices and supply disruption reports from late 2026 to assess the impact of geopolitical events in Iran on oil markets. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify Jensen Huang's resignation status via NVIDIA press releases or SEC filings.
  • Check US inflation data (CPI/PCE) and Federal Reserve meeting minutes for yield drivers.
  • Review Australian RBA minutes and bond market pricing for rate cut expectations.
  • Search ASX announcements for recent private equity bids on small/mid-cap stocks.
  • Read Maine Pharma's binding agreement with Gede Richter and compare protections to the previous COSSET deal.
  • Analyze AMPOL's earnings reports and dividend history to assess cyclical sensitivity.
  • Research global oil supply disruption reports related to the 'Iran war' and their impact on refiner margins.
Full transcriptexpand
0:00
Shannon Rifkin: Good morning members and welcome to this week's Virtually Live. My name is Shannon Rifkin. It is Thursday, the nineteenth of November twenty twenty six. Quick disclaimer this show contains general advice only does not consider your personal circumstances. Um markets still volatile. Um
0:14
Unidentified speaker (UNKNOWN): bit
0:15
Shannon Rifkin: of weakness for sure in the US, um specifically obviously the AI names, which um still reeling from
0:22
Unidentified speaker (UNKNOWN): a
0:22
Shannon Rifkin: sell-off um probably over the last month or so, but uh but certainly uh that is accepted. accelerated with the
0:28
Unidentified speaker (UNKNOWN): um
0:29
Shannon Rifkin: the resignation of of Jensen Huang from from NVIDIA and who's seen kind of as the godfather of the AI sector and obviously the potential implications that's gonna have. Um timing, of course, isn't is couldn't have been worse, I guess, for the sector. Um and really we've seen a sell off there, but there has been a little bit of a rotation as as well. Um and
0:48
Shannon Rifkin: so it hasn't um necessarily impacted the entire market. But of course, you know, we're talking about the biggest companies on uh um on the New York stock exchange, so it has certainly driven uh dragged down the SP five hundred and the NASDAQ, obviously, more specifically. Um but obviously in Australia we have less of an exposure, and I should say as well, you know, we're now starting to
1:08
Shannon Rifkin: see um longer term um bond yields diverge. In the US, obviously the
1:15
Unidentified speaker (UNKNOWN): uh
1:15
Shannon Rifkin: we've seen more strength lately in in yields um because of course uh the AI story is so much more advanced there and and and you know inflation remains very sticky whereas we're starting to see a rate cut next year price into um into the Aussie market even though of course inflation has remained sticky but um obviously we've had a lot of rate
1:35
Shannon Rifkin: rises already uh and there is um likely to be a lag um with the uh with the effect of those. And uh, you know,
1:43
Unidentified speaker (UNKNOWN): at
1:44
Shannon Rifkin: the coal face we're seeing obviously very weak economic conditions um and you know for the most part consumers are doing it very, very tough. So I think um I I think my gut feeling is that that's a pretty accurate um prediction that w what that bond markets are making right now and that we are certainly at or very near the peak. and and you know we
2:04
Shannon Rifkin: might see the r rate cutting cycle you know kick off as soon as you know uh mid early to mid next year. We'll we'll see but obviously that would be very supportive of of risk assets um in general and and and obviously very supportive of the economy um which as as said is doing it tough. Um about to get a question on Maine Pharma and it's an
2:24
Shannon Rifkin: interesting I'll just touch on it but obviously we're seeing more and more of the these uh bids for small and mid caps from from private equity. Um it doesn't seem to stop at the moment um and it shows that and uh as I've said, you know, that that part of the market is look looked at as very undervalued. Um you know, on P multiples, you're not necessarily saying that they're the best uh sorry,
2:44
Shannon Rifkin: that they're the um cheapest offers ever, but what it is is buying um companies at an opportunistic point. in the cycle where these companies have have kind of hit some sort of uh speed bump and and obviously don't have the um the support anymore of the of the market which is obviously so important to get through these these periods and obviously a longer term investor
3:03
Shannon Rifkin: with far more patience and far deeper pockets um is being seen as the the solution to these companies problems and so private equity is filling that void. Um Shame for the ASX and we're not obviously seeing this offset by IPOs. Um, and I've kind of talked about this, you know, the potential for the ASX to become far less relevant over time if all
3:23
Shannon Rifkin: the money flows to the big end of the market, um, and we're just seeing the small ones um dropping like flies. Anyway, I will get into the questions. Um question one, Anthony from Victoria. Hi, Shannon. Interested in your thoughts on Maine Pharma, given the proposed arrangement with Gede and Richter. Is it worth buying it around the current market price of around six dollars? Um look, I
3:43
Shannon Rifkin: glad you asked the question because we have now recommended it. Um is a little bit of PTSD when um you get a second bite of the um uh uh of the Apple with uh
3:53
Unidentified speaker (UNKNOWN): a
3:53
Shannon Rifkin: deal that hasn't gone to plan in the past. It's not the first time. Um
3:58
Unidentified speaker (UNKNOWN): and
3:58
Shannon Rifkin: I think it kind of reflects as well
4:00
Unidentified speaker (UNKNOWN): that what
4:01
Shannon Rifkin: what I just said in that these smaller small mid and caps. cap stocks are cheap through the cycle, looking through the cycle um at the moment. But also, you know, these uh these f fall and over deals, you know, you do see tend to see a d depressed price for a period of time and that leaves them vulnerable to to future approaches. We saw it with uh Link administration, um, which again had
4:21
Shannon Rifkin: a deal fall over and then um sign a new deal not too long after and and now the same with Main Maine Pharma, which is pretty incredible. Obviously, if for us it would have been much better had they found um or had Getty and Richter been willing to do it when all this mess with Cossett was going through the first time around. Um and I should say, you know, everything that has has happened since
4:40
Shannon Rifkin: the deal fell over, um, I kind of supports everything that we were saying at the time. That was an unprecedented um failure. Um, you know, some what's not unprecedented, of course, is that occasionally you'll see buy buy get cold feet. Um that is normal, especially when you know economic conditions change so quickly, and and at least in
5:00
Shannon Rifkin: the pharma market that had been the case because of um Donald Trump's uh plan changes to to pharmaceutical pricing and so on. Um but they signed a binding deal and um and that's what we saw litigated in. in court. Ultimately, um Main Farmer won that in court. But uh
5:20
Shannon Rifkin: you know
5:22
Unidentified speaker (UNKNOWN): the
5:22
Shannon Rifkin: bluff from Cossett that it would close a factory in South Australia both um scared the the South Australian Premier, who who made some noise about it, and then the treasurer um, in my view, fell for what was a pretty obvious bluff. Um that was an asset that was always going to be worth selling ahead of closing.
5:39
Shannon Rifkin: Um and, you know, any attempt to sell jobs was to save jobs was
5:44
Unidentified speaker (UNKNOWN): um p
5:45
Shannon Rifkin: you know futile because the jobs weren't at risk in my view. Um and so what we've seen just before this uh this now deal with getting Richter has been announced is that they had already announced a sale of of uh a division which would include that factory. Um and you know the the value of that asset showed that it was not at risk of being shuttered. So
6:05
Shannon Rifkin: pretty crazy what's happened. Um and I guess the good news of course is without that um asset being there, which I guess maybe the FIB could point to, even though again I think that was a lightning in a bottle situation. We'd never see such stupidity again. Um but that's not no longer going gonna to be an issue obviously 'cause it's not gonna be in the portfolio. Um and
6:25
Shannon Rifkin: the good news as well, again I think
6:27
Shannon Rifkin: this deal looks a lot more rock solid. Um Getty and Richter is
6:33
Shannon Rifkin: a great buyer in that they already sell um and licensed and and uh licensed to sell uh the Next Delos product, which is kind of um Maine's major
6:45
Unidentified speaker (UNKNOWN): um
6:45
Shannon Rifkin: uh drug and and so they obviously know the the product intimately. Um and know the business intimately so that they're a good buyer um uh and so all you know all things being equal I don't think there's going to be issues here. So the return looks good. I think the reason the return looks as good as it as it does of course is that we've seen this um main farmer uh
7:05
Shannon Rifkin: we've seen a main farmer deal fall over of course but you know you need to be objective with these and um take a step back not let emotion um get in the way and I think that provides a us an opportunity to buy it at a really good annualized return. Um and I should say I'm not expecting obviously competing bids, but um but it's not impossible. And obviously this is a very
7:25
Shannon Rifkin: different um this is a much lower offer than the original offer from from COSSET last year, so maybe there's still some more in it. Um although, as I said, very happy buying with the um the current offer on the table.
7:38
Unidentified speaker (UNKNOWN): And
7:38
Shannon Rifkin: Brian from London question two, and I add this because it's a little bit uh it's a little bit of a different discussion, but um hi Shannon, given the history that we had with the last famous month, main farmer takeover, is it worth protecting our investment with a conditional trailing sell order? That way if the takeover suffers the same fate as before, then we get out hopefully before the bottom. Look obviously don't want this to come back and bite me, but
7:58
Shannon Rifkin: to my point earlier, I don't think we should be emotional about this. Every investment um you need to remove emotion from it. S does this deal stand on its own two feet? Um I mean, as I said, I think the COSSET deal stood on its own two feet and you ultimately had a deal that only fell over because the government interfered, which you know when the
8:18
Shannon Rifkin: more I say it the more crazy it sounds, over such a uh over an asset of such little national significance. Um but the uh the treasurer, you know. went ahead and blocked it. Um said I think that's lightning in a bottle. We're never going to see that well we're not going to see that again, I think. Um never say never, but that would be crazy in my view. Um
8:37
Shannon Rifkin: and so, you know, the the binding scheme implementation deed that we you know that I've spent time looking through it looks solid. It in fact it looks like main uh the main board has added you know protections that it I guess it didn't have in that COSSET deal. Um so I think this one looks pretty pretty good. So
8:58
Shannon Rifkin: you can add a a trailing sell order but you know I think I'd prefer rather to say if the stock is weak, you know what's what's the reason for doing it because you know we just saw that for example with um with Reliance which which sold off uh pretty heavily because Australian Super was buying and again that was a if we put in a trailing sell order you'd just be out um
9:18
Shannon Rifkin: and that one's now bounced back and again examining the reason why that sold uh that sold off you know made me very comfortable there was no reason to to tree my holding or get out. And I think that's the same with main pharma. I think it's just best to keep a close eye on it if if we see some selling emerge, merge um try and trying determine to what's going on. Um
9:35
Unidentified speaker (UNKNOWN): But
9:36
Shannon Rifkin: again all things being equal I think this should be a pretty smooth ride. Famous last words of course, 'cause we saw a mess last time, but um but as I said, I think uh we're seeing,
9:45
Unidentified speaker (UNKNOWN): you know,
9:45
Shannon Rifkin: these sort of companies are dropping like flies at the moment. So I I I think um as I said, even in the absence of this deal, I wouldn't be surprised if private equity is is is another buyer as well. But you know, this one looks rock solid. So I'm I'm not nervous. As I said, even though this one if it, you know, were to s were to hit us twice, that would be very, very uh upsetting. But
10:05
Shannon Rifkin: you know, looking over the last five or six years, Main Pharma really does stand out as a as an outlier. Um most of them well sorry, the vast majority have obviously gone through um with with with great results and uh and main farmers I said had a kind of a once in a lifetime sort of reason why it fell over. Uh question three, Greg from Victoria asks, Hi Shannon, is AMPOL a
10:25
Shannon Rifkin: complete sell or is it still viable? as a dividend stock or as a defensive stock? Um I know that sounds crazy, but the government seems willing to latch on to anything that makes them look good. And right now it's one of our last two refiners. Um yeah, look, there's an element of of that kind of government support that makes it more defensive than it would otherwise be. But, you know, I think ultimately this is still very much a
10:45
Shannon Rifkin: cyclical stock and obviously as a dividend stock at these elevated prices as well, very much dependent. on their earnings because it's pays, you know, I think a sixty or s sixty five percent um payout ratio.
10:57
Unidentified speaker (UNKNOWN): Um
10:57
Shannon Rifkin: and ultimately that will f fluctuate depending on its earnings. Right now, of course, refiner margins have skyrocketed. And th in fact I think from this time last year, I think they were around um I think they've up about almost a 150%, hundred and fifty percent. Obviously a direct result of um of this the supply disruptions in the oil markets um from
11:17
Shannon Rifkin: the Iran war. Uh and you know I've
11:21
Shannon Rifkin: I've spoken about this with buying oil and gas stocks as well. And I'd say I consider them more trading stocks right now than investments, um, because obviously in my view the Iran war is not gonna going to obviously um continue forever. Um I do think obviously, especially now that we've seen um change in power through the
11:41
Shannon Rifkin: midterms, um we're more likely to see an exit. Um, even though, you know, I said I think there's been an appetite to exit the war for a while from Donald Trump, but obviously the um the simplicity of that um wasn't what he expected. Um and extra you know extracting himself from this from a bad situation's been very difficult.
12:01
Shannon Rifkin: But I think now he's lost so much power.
12:03
Shannon Rifkin: Um and if he wants, I think the Democrats um in both the House and Senate to work with him on other things, um given how obviously um against this war the Democrats have been, I mean obviously those within his party have been as well, but certainly the Democrats um I think it's highly likely that he ends up taking a much worse deal to get out of
12:23
Shannon Rifkin: this this war. Um and again I don't think this is going to take you know a few more years or the next two years of his term of his term. I think it's it's far more likely to be closer than than far apart far away. So, you know, I think when if that were to happen and we saw um oil prices drop, refiner margins drop, obviously Ampole will
12:43
Shannon Rifkin: sell off significantly. Um it's only a a little bit off its recent highs. Um I mean the fact that it obviously it hasn't gone up as much. as refiner margins has shows that the market's looking through it a little bit. But you know, when that reality hits and and refinery margins start to head south, it won't be immune from that and it won't be seen as a defensive stock. It will, you know, go back to being the cyclical stock
13:03
Shannon Rifkin: it always has been. Um just obviously we're currently in a very good point in the cycle.
13:09
Shannon Rifkin: Um that is it for today. Um thank you very much for getting into questions, appreciate it. Um obviously a lot going on, which is great, and I will be back with you next week.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.

More from Rivkin Investment Podcast

All insights